TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15861940
Drug: Closed wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed wound group (wide resection of skin and subcutaneous tissue, followed by primary closure).
Study: 15861940
Drug: Wide excision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wide excision group (wide resection of skin and subcutaneous tissue, wounds left opened for secondary intention healing).
Study: 12470294
Drug: Intravenous anticholinergic
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anticholinergic
Study: 12470294
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intradeltoid anticholinergics
Study: 2586434
Drug: Chemotherapy (control)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (control) group
Study: 2586434
Drug: OK-432 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OK-432 therapy
Study: 2586434
Drug: Regional infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regional infusion of LAK cells
Study: 31282954
Drug: 224 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 224 mg of edonerpic maleate
Study: 31282954
Drug: 448 mg
Normalized name: omega-3/dha/epa/fish oil 910 mg (308 mg-448 mg-154 mg)-1,400 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 448 mg of edonerpic maleate
Study: 28129772
Drug: Iron polymaltose
Normalized name: iron polymaltose
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron polymaltose (IPM) 6 mg elemental iron/kg/day for 8 weeks
Study: 28129772
Drug: Iron polymaltose
Normalized name: iron polymaltose
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron polymaltose (IPM) in iron-replete children (serum ferritin ≥30 µg/l)
Study: 28129772
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in iron-replete children (serum ferritin ≥30 µg/l)
Study: 28913922
Drug: Hydroxyurea therapy
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea therapy
Study: 14640239
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron dextran (IVFe) infusion to achieve target serum ferritin concentrations of 200 ng/ml
Study: 14640239
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron dextran (IVFe) infusion to achieve target serum ferritin concentrations of 400 ng/ml
Study: 10850936
Drug: HMB/Arg/Gln mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB/Arg/Gln mixture (3 g HMB, 14 g L-glutamine, and 14 g L-arginine given in two divided doses daily for 8 weeks)
Study: 8450520
Drug: Elemental calcium
Normalized name: Elemental calcium
DrugBank: Calcium (DB01373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental calcium (2 g) for 12 weeks
Study: 6330871
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg at night)
Study: 3532297
Drug: Pirenzepine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (50 mg at night)
Study: 3532297
Drug: Antacids (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids (as needed for symptomatic relief)
Study: 30368033
Drug: Food-based micronutrient
Normalized name: food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food-based micronutrient supplement with loyalty cards
Study: 30368033
Drug: Food-based micronutrient
Normalized name: food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food-based micronutrient supplement with price discounts
Study: 30368033
Drug: Retail distribution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retail distribution of micronutrient supplements
Study: 27393520
Drug: 0.45 mg
Normalized name: urea 0.45 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg oral conjugated equine estrogens (CEE)
Study: 27393520
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 (50 μg/d) with micronized P (200 mg daily)
Study: 25027615
Drug: Dextromethorphan hydrobromide
Normalized name: Dextromethorphan Hydrobromide
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan hydrobromide (DM) syrup, age-weight dosing schedule (DM range 7.5-24.75 mg for Groups A and B; 30 mg for Group C)
Study: 25027615
Drug: Dextromethorphan hydrobromide
Normalized name: Dextromethorphan Hydrobromide
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan hydrobromide (DM) syrup
Study: 22419715
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist stimulation (buserelin 100 μg, s.c.) during hyperinsulinemic clamp (80 mU/m2 · min)
Study: 22419715
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist stimulation (buserelin 100 μg, s.c.) during saline infusion
Study: 22419715
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist stimulation (buserelin 100 μg, s.c.) during both hyperinsulinemia and saline infusion
Study: 18616643
Drug: Nitazoxanide 500
Normalized name: nitazoxanide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide 500 mg tablet twice daily for 24 weeks
Study: 18616643
Drug: Nitazoxanide 500
Normalized name: nitazoxanide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide 500 mg tablet
Study: 16088104
Drug: Dialysate bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate bicarbonate at 32 mmol/l (modality A)
Study: 16088104
Drug: Dialysate bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate bicarbonate at 26 mmol/l (modality B)
Study: 16088104
Drug: Dialysate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate calcium at 1.50 mmol/l (modality C)
Study: 16088104
Drug: Subgroup analysis
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup analysis of modality A with ACE inhibitors or angiotensin II blockers
Study: 10613449
Drug: Carboplatin (CBP)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (CBP) 200 mg/m2/day continuous infusion (days 3 to 7) with idarubicin (IDA) 12 mg/m2/day i.v. bolus (days 1 to 3)
Study: 10613449
Drug: Carboplatin (CBP)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (CBP) 200 mg/m2/day continuous infusion (days 3 to 7) with mitoxantrone (MIT) 12 mg/m2/day i.v. bolus (days 1 to 3)
Study: 8526957
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg mivacurium (2 x ED95)
Study: 8526957
Drug: 0.015 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.015 mg/kg mivacurium (20% of ED95) followed by 0.07 mg/kg mivacurium (ED95)
Study: 8526957
Drug: 0.46 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.46 mg/kg atracurium (2 x ED95)
Study: 8526957
Drug: 0.046 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.046 mg/kg atracurium (20% of ED95) followed by 0.23 mg/kg atracurium (ED95)
Study: 1835110
Drug: Nebulised ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised ipratropium 0.5 mg and fenoterol 1.25 mg
Study: 31152023
Drug: Regimen-DI (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen-DI (doxorubicin 6×75 mg/m2/week; cisplatin 6×100 mg/m2/week every 2 weeks)
Study: 31152023
Drug: Regimen-C (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen-C (doxorubicin 6×75 mg/m2/week; cisplatin 6×100 mg/m2/week every 3 weeks)
Study: 28952166
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Haloperidol and Olanzapine)
Study: 18021533
Drug: Control (non-antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-antiviral interventions)
Study: 16330292
Drug: 5 puffs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 puffs of oral insulin spray
Study: 16330292
Drug: 10 puffs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 puffs of oral insulin spray
Study: 16330292
Drug: 20 puffs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 puffs of oral insulin spray
Study: 16330292
Drug: Subcutaneously injected
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously injected regular insulin (0.1 U/kg SC)
Study: 9558132
Drug: Exogenous melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous melatonin administered 5 hours before DLMO
Study: 31531896
Drug: Dynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic treatment regimes (DTRs) for chronic periodontitis
Study: 31531896
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment sharing
Study: 24369765
Drug: Low calorie
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calorie dietary advice + placebo (1 g olive oil)
Study: 24369765
Drug: Low calorie
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calorie dietary advice emphasising fish diet + LCn3PUFA supplements
Study: 21366361
Drug: Dalcetrapib 3900
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 3900 mg single dose
Study: 21366361
Drug: Dalcetrapib 1800-3900
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 1800-3900 mg/day for 7 days
Study: 11743900
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sustained-release theophylline preparation twice daily for 4 weeks
Study: 9210705
Drug: In situ
Approvals — FDA: no, EMA: no, PMDA: no
Description: In situ detection of HCV in liver tissue using a combination of nonradioactive in situ hybridization and immunohistochemistry.
Study: 7950222
Drug: Geng‐Nian‐Shu (GNS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geng‐Nian‐Shu (GNS) treatment
Study: 7950222
Drug: Geng‐Nian‐Shu (GNS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geng‐Nian‐Shu (GNS) treatment in ovariectomized white rats
Study: 31595459
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol sedation
Study: 28806908
Drug: OPT OUT
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OPT OUT - providing all smokers with tobacco-cessation treatment unless they refuse it
Study: 28806908
Drug: OPT IN
Normalized name: Glau-Opt
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPT IN - current practice of screening for readiness and only offering treatment to smokers who say they are ready to quit
Study: 18705917
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 64 mmol/day (16 g/day)
Study: 12826550
Drug: Ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.1% with 0.5 microg x mL(-1) sufentanil (Group R+S0.5)
Study: 12826550
Drug: Ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.1% with 0.75 microg x mL(-1) sufentanil (Group R+S0.75)
Study: 12826550
Drug: Ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.1% with 1 microg x mL(-1) sufentanil (Group R+S1)
Study: 8782501
Drug: Ethanol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (50 ml of 40 percent ethanol)
Study: 29655114
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy and antidepressants (sertraline and mianserin)
Study: 12732833
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid solution G
Study: 12732833
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid solution R
Study: 11048353
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) plus disulfiram
Study: 11048353
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) without disulfiram
Study: 11048353
Drug: Disulfiram (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (in combination with any treatment)
Study: 11048353
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of abstinence during treatment
Study: 8622066
Drug: Amsacrine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amsacrine (100 mg/m2/d on days 1 to 5) and Etoposide (200 mg/m2/d on days 1 to 3)
Study: 8622066
Drug: Amsacrine and
Normalized name: amsacrine
DrugBank: Amsacrine (DB00276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amsacrine and Etoposide plus Azacitidine (250 mg/m2/d on days 4 to 50)
Study: 1473880
Drug: Buffered acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered acetylsalicylic acid (800 mg)
Study: 1473880
Drug: Unbuffered acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unbuffered acetylsalicylic acid (500 mg)
Study: 22326828
Drug: Intratarsal triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratarsal triamcinolone acetonide (TA) injection
Study: 22340928
Drug: Dexamethasone ointment
Normalized name: DEXAMETHASONE 0.075 g in 100 g TOPICAL OINTMENT [Seacall Dexamethasone Ointment.]
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone ointment
Study: 17587715
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum IL-10 level (>= 30 pg/ml)
Study: 17587715
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum IL-10 level (<30 pg/ml)
Study: 10767816
Drug: ACTIVE treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTIVE treatment (24 sessions of proprioceptive exercises, relaxation, and behavioral support)
Study: 10767816
Drug: HOME treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOME treatment (neck lecture and two sessions of practical training for home exercises)
Study: 10767816
Drug: CONTROL treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONTROL treatment (lecture regarding care of the neck with a recommendation to exercise)
Study: 31497883
Drug: Systemic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic Therapy Inventory of Change (STIC) feedback system (ROM condition)
Study: 31497883
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU condition)
Study: 23155977
Drug: Ketamine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine group (intravenous ketamine 0.15 mg/kg pre-induction)
Study: 18069036
Drug: Monthly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly oral ibandronate 150mg for 3 months
Study: 18069036
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral alendronate 70mg for 12 weeks
Study: 16411527
Drug: standard glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard glucose solutions (1.36%)
Study: 2059395
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 to 8 mg/day)
Study: 2059395
Drug: Spironolactone (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (37.5 to 75 mg/day)
Study: 24712568
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg T enanthate
Study: 24712568
Drug: 6.25 mg
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.25 mg T enanthate
Study: 24712568
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg T enanthate
Study: 11788637
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg T enanthate
Study: 21306209
Drug: Ramelteon up
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon up to 16 mg nightly
Study: 18543495
Drug: Safflor yellow
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflor yellow powder injection (150 mg/d) + Benazepril (10 mg/day)
Study: 18543495
Drug: Benazepril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (10 mg/day)
Study: 10080880
Drug: EPO+high Fe
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO+high Fe (200 U/kg/other day of rhEPO + 12 mg/kg/day of iron)
Study: 10080880
Drug: EPO+standard Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO+standard Fe (200 U/kg/other day of rhEPO + 4 mg/kg/day of iron)
Study: 10080880
Drug: Standard Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Fe (4 mg/kg/day of iron only)
Study: 2202451
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg prednisolone daily
Study: 2202451
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg prednisolone daily
Study: 31654779
Drug: Teriparatide (20μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20μg subcutaneous daily)
Study: 31654779
Drug: Benzodiazepines/hypnotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines/hypnotics
Study: 31654779
Drug: Risedronate (35mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (35mg oral weekly)
Study: 31010058
Drug: High fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat oral nutritional supplement (HFS)
Study: 19300423
Drug: 4.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g/day CLA with 37.5 mg/day ramipril
Study: 19300423
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 37.5 mg/day ramipril
Study: 15352910
Drug: Orlistat treatment
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat treatment for 6 months
Study: 11672759
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg intravenous acetylsalicylic acid (ASA)
Study: 26183588
Drug: Physical therapists'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapists' treatment orientations or attitudes
Study: 25424931
Drug: Vaccine recipients
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine recipients (large-scale cohort)
Study: 23512639
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) + venlafaxine extended-release (VXR)
Study: 23512639
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) or LDX + venlafaxine extended-release (VXR)
Study: 20518254
Drug: MAK (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAK (1.5 g/day) for 12 months
Study: 12412571
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for Helicobacter pylori eradication
Study: 1827125
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day CPA
Study: 6261782
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg oral salbutamol
Study: 27822319
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil (800 mg DHA/day)
Study: 19049481
Drug: Spironolactone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (100 mg three times daily)
Study: 12936920
Drug: Test meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test meal + 0.5 g alcohol/kg body wt (M+A)
Study: 10762288
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose GH therapy (1 U (0.5 mg) subcutaneously per day, n = 5)
Study: 10762288
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose GH therapy (2 U daily, n = 5)
Study: 10762288
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy after placebo (n = 5)
Study: 1597852
Drug: Purified caffeine
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified caffeine (200 mg)
Study: 31206607
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg rabbit anti-thymocyte globulin (ATG) for 5 days
Study: 31206607
Drug: 3.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg/kg rabbit anti-thymocyte globulin (ATG) for 5 days
Study: 20523078
Drug: Oral risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral risperidone orodispersible tablet
Study: 18670740
Drug: Irbesartan (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150-300 mg)
Study: 18670740
Drug: Quinapril (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (20-40 mg)
Study: 16440578
Drug: Calcipotriol cream
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol cream applied once daily
Study: 16440578
Drug: Calcipotriol cream
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol cream applied twice daily
Study: 8889909
Drug: Fluvoxamine (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100-150 mg/day)
Study: 1907963
Drug: Fluoxetine (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20-80 mg/day)